C4 Therapeutics, Inc. (CCCC)
NASDAQ: CCCC · Real-Time Price · USD
2.950
-0.190 (-6.05%)
At close: Oct 2, 2026, 4:00 PM EDT
3.004
+0.054 (1.82%)
After-hours: Oct 2, 2026, 7:30 PM EDT
C4 Therapeutics Employees
C4 Therapeutics had 104 employees as of December 31, 2025. The number of employees decreased by 6 or -5.45% compared to the previous year.
Employees
104
Change (1Y)
-6
Growth (1Y)
-5.45%
Revenue / Employee
$336,913
Profits / Employee
-$975,154
Market Cap
362.92M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 104 | -6 | -5.45% |
| Dec 31, 2024 | 110 | -35 | -24.14% |
| Dec 31, 2023 | 145 | -1 | -0.68% |
| Dec 31, 2022 | 146 | 25 | 20.66% |
| Dec 31, 2021 | 121 | 22 | 22.22% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Arcturus Therapeutics Holdings | 111 |
| Editas Medicine | 87 |
| Orchestra BioMed Holdings | 86 |
| Agenus | 81 |
| Prelude Therapeutics | 79 |
| Zura Bio | 40 |
| Opus Genetics | 28 |
| vTv Therapeutics | 26 |
CCCC News
- 8 days ago - C4 Therapeutics Slides: Corporate presentation - Filings
- 8 days ago - C4 Therapeutics presents biomarker data from Phase 1 trial of cemsidomide - TheFly
- 8 days ago - C4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab (ELREXFIO®) in Relapsed/Refractory Multiple Myeloma at the 23rd International Myeloma Society (IMS) Annual Meeting - GlobeNewsWire
- 23 days ago - C4 Therapeutics Transcript: Wells Fargo 21st Annual Healthcare Conference - Transcripts
- 4 weeks ago - C4 Therapeutics to Present New Biomarker Data on the Immunomodulatory Effects of Cemsidomide in Combination with Dexamethasone from its Phase 1 Relapsed/Refractory Multiple Myeloma Trial at the 23rd International Myeloma Society (IMS) Annual Meeting - GlobeNewsWire
- 7 weeks ago - C4 Therapeutics reports Q2 EPS (18c), consensus (23c) - TheFly
- 7 weeks ago - C4 Therapeutics Earnings release: Q2 2026 - Filings
- 7 weeks ago - C4 Therapeutics Quarterly report: Q2 2026 - Filings